10-Q: Applied DNA Sciences Reports Q2 2025 Results, Focuses on Therapeutic DNA Production

Applied DNA Sciences is shifting its focus to Therapeutic DNA Production Services after exiting its DNA Tagging and Security Products and Services business, reporting a net loss of $6.0 million for the six months ended March 31, 2025.

Summary

• Applied DNA Sciences reported a net loss of $6.0 million for the six months ended March 31, 2025, and negative operating cash flow of $6.5 million.
• The company is focusing on its Therapeutic DNA Production Services, including the LineaDNA and Linea IVT platforms.
• Applied DNA Sciences exited its DNA Tagging and Security Products and Services business in February 2025, resulting in a 20% workforce reduction and $305,000 in one-time personnel-related charges.
• A strategic review of the MDx Testing Services business segment is ongoing.
• Product revenues increased by 49% to $1.04 million for the six-month period, driven by large-scale DNA manufacturing.
• Service revenues increased by 30% to $588,628, primarily due to isotopic testing services for textiles.
• Clinical laboratory service revenues decreased by 18% to $546,878 due to reduced COVID-19 testing demand.
• The company completed a 1-for-50 reverse stock split on March 14, 2025.
• A registered direct offering in October 2024 generated net proceeds of approximately $5.7 million.
• The company identified a material weakness in internal control over financial reporting related to fair value calculations for warrant modifications.
• The company plans to offer GMP-grade LineaDNA for biologic, drug substance, and drug product applications, with availability expected in the first half of CY 2026, contingent on funding.
• ADCL submitted a validation package to NYSDOH for influenza A (H5) virus testing.
• The company's cash and cash equivalents were $6.8 million as of March 31, 2025.
• The company has substantial doubt about its ability to continue as a going concern.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are some positive trends in revenue growth, the company is still experiencing significant losses and faces substantial doubt about its ability to continue as a going concern. The material weakness in internal control and the need for additional funding add to the negative sentiment.

Positives

• Product revenues increased by 49% to $1.04 million for the six-month period, driven by large-scale DNA manufacturing.
• Service revenues increased by 30% to $588,628, primarily due to isotopic testing services for textiles.
• The company is focusing on its Therapeutic DNA Production Services, which has a large potential market.
• GMP site 1 achieved operation status as of January 31, 2025.
• ADCL submitted a validation package to NYSDOH for influenza A (H5) virus testing.

Negatives

• The company reported a net loss of $6.0 million and negative operating cash flow of $6.5 million for the six months ended March 31, 2025.
• Clinical laboratory service revenues decreased by 18% to $546,878 due to reduced COVID-19 testing demand.
• The company identified a material weakness in internal control over financial reporting related to fair value calculations for warrant modifications.
• The company has substantial doubt about its ability to continue as a going concern.
• The closing price of the company's common stock is currently below $1.00.

Risks

• The company's ability to continue as a going concern is dependent on raising capital and generating revenues.
• The company's stock price may be delisted from Nasdaq if it fails to comply with the $1.00 minimum price requirement.
• The company's Laboratory Developed Tests (LDTs) may become subject to additional regulatory requirements.
• The company's success depends on the demand for Therapeutic DNA Production Services and MDx Testing Services.
• The company faces risks related to regulatory approval and compliance for its Therapeutic DNA Production Services.
• The company's stockholders may suffer substantial dilution if certain provisions of its outstanding warrants are utilized.
• The reverse stock split may decrease the liquidity of the shares of the company's common stock.

Future Outlook

The company plans to focus on expanding its Therapeutic DNA Production Services, including offering GMP-grade LineaDNA for biologic, drug substance, and drug product applications, with availability expected in the first half of CY 2026, contingent on funding. The company also plans to leverage its PGx Testing Services to provide PGx testing services to large entities, self-insured employers and other types of healthcare providers.

Management Comments

• The company's management has also been and currently remains engaged in a strategic review of its MDx Testing Services business segment.
• We expect that based on available opportunities and our beliefs regarding future opportunities, we will continue to modify and refine our business strategy.

Industry Context

The company is positioning itself to capitalize on the growing market for mRNA therapies and nucleic acid-based therapeutics. The company believes that the mRNA market is in a nascent stage that represents a large growth opportunity for the Company via the production and supply of DNA critical starting materials and RNAP to produce mRNA therapies.

Comparison to Industry Standards

• The document mentions ASGCT Gene, Cell & RNA Therapy Landscape: Q1 2025 Quarterly Report as a source for industry data.
• The document mentions that as of the first quarter of calendar year 2025, there were 4,418 gene, cell and RNA therapies in development from preclinical through pre-registration stages, almost all of which use DNA in their manufacturing process.
• The document mentions that as of the first quarter of calendar 2025, there were over 450 mRNA therapies under development, with the majority of these therapies (65%) in the preclinical stage.

Stakeholder Impact

• Shareholders face the risk of dilution and potential delisting from Nasdaq.
• Employees have experienced workforce reductions.
• Customers may be impacted by the company's strategic shift and potential changes in service offerings.
• Creditors face increased risk due to the company's going concern uncertainty.

Next Steps

• The company plans to offer GMP-grade LineaDNA for biologic, drug substance, and drug product applications, with availability expected in the first half of CY 2026, contingent on funding.
• The company is seeking to obtain Warrant Stockholder Approval at the Annual Meeting of Stockholders to be held on May 22, 2025.
• The company plans to leverage its PGx Testing Services to provide PGx testing services to large entities, self-insured employers and other types of healthcare providers.
• ADCL is awaiting NYSDOH approval for its influenza A (H5) virus testing.

Key Dates

Keywords

Therapeutic DNA Production Services, LineaDNA, Linea IVT, MDx Testing Services, Reverse Stock Split, Warrants, Net Loss, Revenue, GMP, COVID-19, H5 bird flu